|Bid||18.76 x 900|
|Ask||18.77 x 800|
|Day's Range||18.06 - 18.78|
|52 Week Range||10.81 - 21.25|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2023 - Mar 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
Subscribe to Yahoo Finance Plus to view Fair Value for ICPT
Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.